A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer

Journal of Urology

Volumn 188, Issue 6, 2012, Pages 2391-2397

  Burke, James M ^a   Lamm, Donald L ^b   Meng, Maxwell V ^c   Nemunaitis, John J ^e   Stephenson, Joseph J ^g   Arseneau, James C ^h   Aimi, Junko ^d   Lerner, Seth ^f   Yeung, Alex W ^d   Kazarian, Troy ^d   Maslyar, Daniel J ^d   McKiernan, James M ⁱ  

^a BILLINGS CLINIC   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CELL GENESYS INC   (United States)

^e Mary Crowley Medical Research Center   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g Cancer Centers of the Carolinas   (United States)

^h Albany Regional Cancer Center   (United States)

ⁱ Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Adenoviridae; dose response relationship; immunologic; toxicity; urinary bladder; urinary bladder neoplasms

Indexed keywords

ANTINEOPLASTIC AGENT; CG 0070; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ONCOLYTIC ADENOVIRUS; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BLADDER DISCOMFORT; BLADDER SPASM; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; CYSTOSCOPY; DYSURIA; FATIGUE; HEMATURIA; HUMAN; IMMUNOHISTOCHEMISTRY; MYALGIA; NOCTURIA; NON MUSCLE INVASIVE BLADDER CANCER; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETINOBLASTOMA; RETROSPECTIVE STUDY; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT RESPONSE; URINALYSIS; URINARY FREQUENCY; URINE CYTOLOGY; VIRUS REPLICATION;

ADENOVIRUSES, HUMAN; ADMINISTRATION, INTRAVESICAL; ADULT; AGED; CYSTOSCOPY; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; ONCOLYTIC VIROTHERAPY; PATIENT SELECTION; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84869095632     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2012.07.097     Document Type: Article

References (26)

1. R. Siegel, E. Ward, O. Brawley Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths Cancer J Clin 61 2011 212
2. H.W. Herr, G. Jakse, J. Sheinfeld The T1 bladder tumor Semin Urol 8 1990 254
3. J.A. Witjes Management of BCG failures in superficial bladder cancer: a review Eur Urol 49 2006 790
4. S. Barmoshe, A.R. Zlotta Prognosis of T1G3 tumors: clinical factors Eur Urol 3 suppl. 2004 73
5. M.C. Hall, S.S. Chang, G. Dalbagni Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update J Urol 178 2007 2314
6. M.A. O'Donnell Combined bacillus Calmette-Guerin and interferon use in superficial bladder cancer Expert Rev Anticancer Ther 3 2003 809
7. H.W. Herr, D.M. Schwalb, Z.F. Zhang Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial J Clin Oncol 13 1995 1404
8. R. De Jager, P. Guinan, D. Lamm Long-term complete remission in bladder carcinoma in situ with intravesical TICE bacillus Calmette Guerin Overview analysis of six phase II clinical trials Urology 38 1991 507
9. A.R. Zlotta, N.E. Fleshner, M.A. Jewett The management of BCG failure in non-muscle-invasive bladder cancer: an update Can Urol Assoc 3 suppl. 2009 S199 J
10. J.C. Kim, G.D. Steinberg The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder J Urol 165 2001 745
11. M.A. O'Donnell, K. Lilli, C. Leopold et al. Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer J Urol 172 2004 888
12. G. Steinberg, R. Bahnson, S. Brosman Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder The Valrubicin Study Group J Urol 163 2000 761
13. N. Ramesh, Y. Ge, D.L. Ennist CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor-armed oncolytic adenovirus for the treatment of bladder cancer Clin Cancer Res 12 2006 305
14. N.M. Luis, E. López-Knowles, F.X. Real Molecular biology of bladder cancer Clin Transl Oncol 9 2007 5
15. M. Castillo-Martin, J. Domingo-Domenech, O. Karni-Schmidt Molecular pathways of urothelial development and bladder tumorigenesis Urol Oncol 28 2010 401
16. N. Ramesh, B. Memarzadeh, Y. Ge Identification of pretreatment agents to enhance adenovirus infection of bladder epithelium Mol Ther 10 2004 697
17. B.E. Storer Design and analysis of phase I clinical trials Biometrics 45 1989 925
18. E.A. Eisenhauer, P.J. O'Dwyer, M. Christian Phase I clinical trial design in cancer drug development J Clin Oncol 18 2000 684
19. A.A. Dario Vignali multiplexed particle-based flow cytometric assays J Immunol Methods 243 2000 243
20. W.F. Benedict, S.P. Lerner, J. Zhou Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer Oncogene 18 1999 1197
21. L.C. Pagliaro, A. Keyhani, D. Williams Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy J Clin Oncol 21 2003 2247
22. C.P. Dinney, W.F. Benedict, D.L. Cutler A phase I study of intravesical Ad-IFN in superficial bladder cancer patients J Clin Oncol 27 suppl. 2009 abstract e16048
23. J.L. Chong, P.L. Wenzel, M.T. Sáenz-Robles E2F1-3 Switch from activators in progenitor cells to repressors in differentiating cells Nature 462 2009 930
24. S.J. Chatterjee, B. George, P.J. Goebell Hyperphosphorylation of pRb: a mechanism for RB tumor suppressor pathway inactivation in bladder cancer J Pathol 203 2004 762
25. N.N. Senzer, H.L. Kaufman, T. Amatruda Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpes virus in patients with unresectable metastatic melanoma J Clin Oncol 27 2009 5763
26. C.J. Breitbach, J. Burke, D. Jonker Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans Nature 477 2011 99